Liver-cancer prevention starts with protecting the liver and identifying conditions that need ongoing care. The most useful questions concern hepatitis, liver scarring, alcohol and metabolic health, food exposures, and whether a specialist recommends surveillance.
Identify the kind of risk
This guide concerns cancer that begins in the liver, especially hepatocellular carcinoma (HCC). Cancer that spreads to the liver from another organ is managed according to its original cancer type. A prevention checklist cannot estimate the outlook of an existing metastatic cancer.
HCC often develops in the setting of chronic liver disease. NCI’s liver-cancer risk overview identifies chronic hepatitis B or C, cirrhosis, heavy alcohol use, certain metabolic liver conditions and aflatoxin exposure among the relevant risks. Having a risk factor calls for assessment; it does not establish that cancer will develop.
Bring previous hepatitis results, liver imaging, medication and supplement lists, and any diagnosis of fatty liver or cirrhosis to a primary-care or liver appointment. Ask which findings are confirmed and which still need evaluation. A remembered “normal liver test” is less useful than the actual report and date.
For the distinction between a cancer’s origin and the organ where it is found, see how metastatic cancers are named.
Clarify hepatitis testing and care
Hepatitis B vaccination prevents HBV infection. CDC’s hepatitis B guidance recommends at least one lifetime screening for U.S. adults, with further testing according to risk. Ask a clinician to interpret your test results together and review vaccination eligibility and records. Vaccination and the management of an established infection serve different purposes.
For hepatitis C, CDC explains that oral antiviral treatment can cure most infections. Testing connects people to this treatment even when they feel well. Ask how cure will be confirmed and what liver follow-up will remain appropriate. There is no hepatitis C vaccine.
If chronic hepatitis B is present, a clinician assesses whether antiviral treatment is indicated and how to monitor the liver. Discuss ways to reduce blood and sexual exposure risks and whether household or sexual contacts need testing or vaccination. Use the care team’s instructions for your circumstances.
Separate prevention from surveillance
On a small screen, scroll the table sideways. Keyboard users can focus the table region and use the arrow keys.
| Task | Purpose | Question to ask |
|---|---|---|
| Risk reduction | Prevent infection and reduce ongoing liver injury or harmful exposures. | Which actions or treatments apply to my history? |
| Cancer surveillance | Repeat testing in an eligible higher-risk group to look for cancer earlier. | Do I qualify, which tests are planned, and who tracks them? |
| Diagnostic evaluation | Investigate a symptom, lesion or abnormal result. | What does this finding require, and when? |
The AASLD hepatocellular-carcinoma practice guidance recommends ultrasound with a blood test for alpha-fetoprotein (AFP), generally about every six months, for appropriate at-risk groups. Eligibility depends on factors including cirrhosis, hepatitis B history and whether cancer treatment would be feasible. This is a specialist surveillance plan, not a universal screening schedule.
Successful hepatitis treatment can reduce risk while leaving a need for surveillance in some people, particularly those with cirrhosis. Ask for a written plan instead of assuming that one improved result ends follow-up. New symptoms need assessment on their own timetable.
Reduce continuing liver injury and exposure
Discuss alcohol use openly and ask what change is appropriate for your liver condition. A clinician can help plan safe reduction if dependence or withdrawal is a concern. If you have metabolic liver disease, work with the team on diabetes, activity, nutrition and weight-related goals that fit your health and resources. Smoking cessation also belongs in a risk-reduction plan.
Aflatoxins are toxins made by certain molds that can contaminate foods such as grains and nuts. NCI’s aflatoxin guidance explains the liver-cancer association and exposure reduction. Follow local food-safety advice, buy from reliable regulated suppliers, store foods as directed, and discard nuts that are moldy, discolored or shriveled. A food’s appearance cannot certify that it is free of contamination; supplier controls and food regulation matter too.
Read supplement claims by their measured outcome
A 2001 randomized chlorophyllin study in Qidong, China measured a urinary marker of aflatoxin-related DNA damage in an exposed population. A lower biomarker level is evidence about that measured pathway. Demonstrating fewer liver cancers would require cancer outcomes and suitable follow-up.
Keep three questions together when reading such a claim: Who was exposed? What changed in the study? Did researchers measure cancer diagnoses or a laboratory marker? A supplement marketed with the word “detox” does not supply those answers. Review supplements with your clinician, especially when liver disease or prescription treatment is present.
Leave with a specific next step
- Which liver condition or infection do I have, and what evidence confirms it?
- Do I need hepatitis testing, vaccination, treatment or specialist referral?
- Does my risk justify cancer surveillance? Who schedules and explains each result?
- Which medicines, supplements, alcohol or food-exposure questions need review?
- What new symptoms should prompt a call, and which contact should I use?
For the broader picture, see practical cancer risk reduction.
Updated October 9, 2026. General education for conversations with qualified health professionals; individual care depends on your history, results and local guidance.
Explore the Cancer guides and topic directory.